---
schema_version: "secwatch.filing_event.v1"
accession: "0001161697-22-000375"
form_type: "8-K"
ticker: "KRMD"
cik: "0000704440"
company_name: "KORU Medical Systems, Inc."
filed_at: "2022-08-03T23:59:59+00:00"
generated_at: "2026-06-24T05:30:57.048105+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# KORU Medical Q2 net sales up 18.4% to $6.5M; raises FY revenue guidance but lowers margin forecast

## Summary
- Net sales $6.5M (+18.4% YoY) driven by novel therapies (NRE milestone) and core growth; backorders $0.3M.
- GAAP net loss $2.9M (EPS -$0.07) vs $1.1M loss a year ago; adjusted EPS -$0.06.
- Raises FY 2022 revenue guidance to $27.0–27.5M (from $26.5–27.0M); lowers gross margin guidance to 55–60% (from 60%).
- Manufacturing transfer to contract manufacturer delayed to Q1 2023 (from Q4 2022); cash $18.3M at quarter end.
- Expanded novel therapies pipeline with two new biopharmaceutical agreements.

## SEC filing metadata
- accession: 0001161697-22-000375
- form_type: 8-K
- ticker: KRMD
- cik: 0000704440
- company_name: KORU Medical Systems, Inc.
- filed_at: 2022-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/704440/000116169722000375/0001161697-22-000375-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/704440/000116169722000375/form_8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001161697-22-000375
- JSON: https://secwatch.observer/filing/0001161697-22-000375.json
- Plain text: https://secwatch.observer/filing/0001161697-22-000375.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.